EP Patent

EP3708163A1 — Use of sparsentan for the treatment of chronic inflammatory diseases

Assigned to Ligand Pharmaceuticals Inc · Expires 2020-09-16 · 6y expired

What this patent protects

Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

USPTO Abstract

Methods of administering and pharmaceutical compositions of a biphenyl sulphonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases.

Drugs covered by this patent

Patent Metadata

Patent number
EP3708163A1
Jurisdiction
EP
Classification
—
Expires
2020-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Ligand Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.